罗氏报告了对petrelintide的有希望的第二阶段结果,这是一种在肥胖患者中引起显著体重减轻的实验药物,支持其进一步发展. Roche reports promising Phase II results for petrelintide, an experimental drug that caused significant weight loss in obese patients, supporting its further development.

Roche宣布了对石丁酸的第二阶段试验的积极结果,目前正在开发一种实验性阿米林类比,以治疗超重和肥胖症。 Roche has announced positive Phase II trial results for petrelintide, an experimental amylin analog being developed to treat overweight and obesity. 该药物给参与者带来了大量减重的好处,其结果支持了临床的进一步发展。 The drug showed significant weight loss benefits in participants, with results supporting further clinical development. 研究结论由Roche子公司Genentech提出,强调在日益增长的肥胖治疗市场中,石丁酸作为一种新治疗方案的潜力。 The findings were presented by Genentech, a Roche subsidiary, and highlight the potential of petrelintide as a new treatment option in the growing obesity therapeutics market.